An assessment of the risk, cost-effectiveness, and perceived benefits of anti-parvovirus B19 tested blood products.

CONCLUSION: The estimated mortality and morbidity caused by B19V infection was low in the risk groups. The cost-effectiveness ratio is similar to other blood safety screening measures. No guidance exists to evaluate the acceptability of this ratio. The explicit overview of costs and effects may further guide the discussion of the desirability of B19V safe blood products.
PMID: 31032994 [PubMed - as supplied by publisher]

Source: Transfusion - April 28, 2019 Category: Hematology Authors: van Hoeven LR, Janssen MP, Lieshout-Krikke RW, Molenaar-de Backer MW Tags: Transfusion Source Type: research